Advertisement

Clinical Significance of the Thioredoxin System and Thioredoxin-Domain-Containing Protein Family in Hepatocellular Carcinoma

  • Sang Yeon Cho
  • Sungha Kim
  • Mi-Ju Son
  • Woo Sun Rou
  • Seok Hyun Kim
  • Hyuk Soo Eun
  • Byung Seok Lee
Original Article

Abstract

Background

Oxidative stress occurs due to the excessive generation of cellular reactive oxygen species and antioxidant system dysfunction. The thioredoxin (TXN) system and TXN-domain-containing protein (TXNDC) family form networks maintaining the cellular reducing environment. Recently, the importance of these genes in the tumor environment has been emphasized.

Aim

To investigate the clinical significance of TXNs and TXNDC family members in HCC.

Methods

Genomic data from 367 hepatocellular carcinoma (HCC) patients who underwent hepatic resections were analyzed to determine genetic alterations in mRNA and protein levels between patients and healthy controls. In addition, functional enrichment and survival analyses were performed.

Results

HCC patients were shown to have enhanced expression of TXN, TXNRD1, and TXNDC7/9/14 mRNA and protein compared with controls. In accordance with the survival analyses, strong associations were found that patients with TXN, TXNRD1, and TXNDC1/7/9 alterations were proven to have poor prognosis in overall survival. Moreover, gene set enrichment analysis and network analyses revealed that positive correlations were found in mRNA expression of TXN, TXNRD1, and TXNDC7/9 genes with upregulation of the tumor-promoting genes, specifically mTORC1, E2F targets, and Myc targets. On the other hand, elevated expressions of TXNIP and TXNDC11 genes were correlated with suppression of the above tumor-promoting genes.

Conclusions

TXN system and TXNDC family gene panel obtained from the resected tissue of the HCC patients could be used to predict survival prognosis of HCC, and these genes could be considered as potential therapeutic targets for improving HCC survival.

Keywords

Thioredoxin TXN-domain-containing protein Hepatocellular carcinoma Overall survival 

Notes

Funding

This work was supported by a grant from the Korea Institute of Oriental Medicine (K18123) and the National Research Foundation of Korea funded by the Korea Government (NRF-2017R1C1B1004924).

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest and financial arrangements.

Availability of data and materials

The datasets analyzed during the current study are available in TCGA (http://cancergenome.nih.gov/) and Firebrowse (http://firebrowse.org/).

Ethics approval and consent to participate

Ethical approval was not required as the study used data available on the database Firebrowse (http://firebrowse.org/).

References

  1. 1.
    Casas-Grajales S, Muriel P. Antioxidants in liver health. World J Gastrointest Pharmacol Ther. 2015;6:59–72.CrossRefGoogle Scholar
  2. 2.
    Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49:1603–1616.CrossRefGoogle Scholar
  3. 3.
    Wang Z, Li Z, Ye Y, Xie L, Li W. Oxidative stress and liver cancer: etiology and therapeutic targets. Oxid Med Cell Longev. 2016;2016:7891574.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Cheng SB, Liu HT, Chen SY, et al. Changes of oxidative stress, glutathione, and its dependent antioxidant enzyme activities in patients with hepatocellular carcinoma before and after tumor resection. PLoS ONE. 2017;12:e0170016.CrossRefGoogle Scholar
  5. 5.
    Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12:931–947.CrossRefGoogle Scholar
  6. 6.
    Trachootham D, Zhou Y, Zhang H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell. 2006;10:241–252.CrossRefGoogle Scholar
  7. 7.
    Mahmood DF, Abderrazak A, El Hadri K, Simmet T, Rouis M. The thioredoxin system as a therapeutic target in human health and disease. Antioxid Redox Signal. 2013;19:1266–1303.CrossRefGoogle Scholar
  8. 8.
    Kakolyris S, Giatromanolaki A, Koukourakis M, et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res. 2001;7:3087–3091.PubMedGoogle Scholar
  9. 9.
    Raffel J, Bhattacharyya AK, Gallegos A, et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med. 2003;142:46–51.CrossRefGoogle Scholar
  10. 10.
    Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 2002;62:5089–5095.PubMedGoogle Scholar
  11. 11.
    Berggren M, Gallegos A, Gasdaska JR, et al. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res. 1996;16:3459–3466.PubMedGoogle Scholar
  12. 12.
    Fu B, Meng W, Zeng X, et al. TXNRD1 is an unfavorable prognostic factor for patients with hepatocellular carcinoma. Biomed Res Int. 2017;2017:4698167.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM. The thioredoxin–thioredoxin reductase system: over-expression in human cancer. Anticancer Res. 2003;23:2425–2433.PubMedGoogle Scholar
  14. 14.
    Mollbrink A, Jawad R, Vlamis-Gardikas A, et al. Expression of thioredoxins and glutaredoxins in human hepatocellular carcinoma: correlation to cell proliferation, tumor size and metabolic syndrome. Int J Immunopathol Pharmacol. 2014;27:169–183.CrossRefGoogle Scholar
  15. 15.
    Morrison JA, Pike LA, Sams SB, et al. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. Mol Cancer. 2014;13:62.CrossRefGoogle Scholar
  16. 16.
    Shen L, O’Shea JM, Kaadige MR, et al. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proc Natl Acad Sci USA. 2015;112:5425–5430.CrossRefGoogle Scholar
  17. 17.
    Zhou J, Yu Q, Chng WJ. TXNIP (VDUP-1, TBP-2): a major redox regulator commonly suppressed in cancer by epigenetic mechanisms. Int J Biochem Cell Biol. 2011;43:1668–1673.CrossRefGoogle Scholar
  18. 18.
    Hanschmann EM, Godoy JR, Berndt C, Hudemann C, Lillig CH. Thioredoxins, glutaredoxins, and peroxiredoxins—molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling. Antioxid Redox Signal. 2013;19:1539–1605.CrossRefGoogle Scholar
  19. 19.
    Horna-Terrón E, Pradilla-Dieste A, Sánchez-de-Diego C, Osada J. TXNDC5, a newly discovered disulfide isomerase with a key role in cell physiology and pathology. Int J Mol Sci. 2014;15:23501–23518.CrossRefGoogle Scholar
  20. 20.
    Lu A, Wangpu X, Han D, et al. TXNDC9 expression in colorectal cancer cells and its influence on colorectal cancer prognosis. Cancer Invest. 2012;30:721–726.CrossRefGoogle Scholar
  21. 21.
    Zhang S-F, Wang X-Y, Fu Z-Q, et al. TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer. Autophagy. 2015;11:225–238.CrossRefGoogle Scholar
  22. 22.
    Wondrak GT. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal. 2009;11:3013–3069.CrossRefGoogle Scholar
  23. 23.
    Eun HS, Cho SY, Joo JS, et al. Gene expression of NOX family members and their clinical significance in hepatocellular carcinoma. Sci Rep. 2017;7:11060.CrossRefGoogle Scholar
  24. 24.
    Li J, Cheng ZJ, Liu Y, et al. Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma. Oncotarget. 2015;6:9551–9563.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Miyazaki K, Noda N, Okada S, et al. Elevated serum level of thioredoxin in patients with hepatocellular carcinoma. Biotherapy. 1998;11:277–288.CrossRefGoogle Scholar
  26. 26.
    Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem. 2000;267:6102–6109.CrossRefGoogle Scholar
  27. 27.
    Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9–22.CrossRefGoogle Scholar
  28. 28.
    Thangavelu PU, Lin CY, Vaidyanathan S, et al. Overexpression of the E2F target gene CENPI promotes chromosome instability and predicts poor prognosis in estrogen receptor-positive breast cancer. Oncotarget. 2017;8:62167–62182.CrossRefGoogle Scholar
  29. 29.
    Goldberg SF, Miele ME, Hatta N, et al. Melanoma metastasis suppression by chromosome 6: evidence for a pathway regulated by CRSP3 and TXNIP. Cancer Res. 2003;63:432–440.PubMedGoogle Scholar
  30. 30.
    Han SH, Jeon JH, Ju HR, et al. VDUP1 upregulated by TGF-β1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene. 2003;22:4035.CrossRefGoogle Scholar
  31. 31.
    Li J, Yue Z, Xiong W, et al. TXNIP overexpression suppresses proliferation and induces apoptosis in SMMC7221 cells through ROS generation and MAPK pathway activation. Oncol Rep. 2017;37:3369–3376.CrossRefGoogle Scholar
  32. 32.
    Sinha K, Das J, Pal PB, Sil PC. Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis. Arch Toxicol. 2013;87:1157–1180.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.School of MedicineChungnam National UniversityDaejeonRepublic of Korea
  2. 2.Department of Clinical ResearchKorea Institute of Oriental MedicineDaejeonRepublic of Korea
  3. 3.Department of Internal MedicineChungnam National University HospitalDaejeonRepublic of Korea
  4. 4.Department of Internal Medicine, School of MedicineChungnam National UniversityDaejeonRepublic of Korea

Personalised recommendations